Other Events. On August 17, 2026, the Company issued a press release announcing the Private Placement. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

Entry Into a Material Definitive Agreement. On August 16, 2026, Dermata Therapeutics, Inc. (the “ Company ”) entered into securities purchase agreements (the “ Purchase Agreement ”) with certain institutional and accredited investors, for the issuance and sale in a private placement (the “ Private Placement ”) of (i) 933,064 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), (ii) pre-funded warrants (“ Pre-Funded Warrants ”) to purchase…

Unregistered Sales of Equity Securities. The information contained in

as Exhibit 99.1. The information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information contained in this

Other Events. On August 5, 2026, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing the Company’s anticipated launch date for its first commercial product, Tome Foundational Treatment. The Company expects the Foundational Treatment to be available for sale, starting on August 25, 2026, with those on the waitlist getting early access to preorder. The Foundational Treatment set includes four once-weekly treatments and will be available exclusively through www.tomeskinc…

The filing describes an amendment to the equity incentive plan, which is not a management change.

as Exhibit 99.1. The information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information contained in this

as Exhibit 99.1. The information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information contained in this

Director — Mary Fisher: Ms. Fisher resigned due to her new employer's restrictions.

Changes in Registrant’s Certifying Accountant. (a) Dismissal of independent registered public accounting firm. On January 30, 2026, Dermata Therapeutics, Inc. (the “Company”) notified Baker Tilly US, LLP (formerly Moss Adams LLP) (“Baker Tilly”) that Baker Tilly would be dismissed as the Company’s independent registered public accounting firm. The Company’s Audit Committee of the Board of Directors (the “Audit Committee”) approved the decision to dismiss Baker Tilly, which will become effecti…

Other Events. On January 27, 2026, Dermata Therapeutics, Inc. (the “Company”) filed a prospectus supplement (the “Current Prospectus Supplement”) to increase the maximum aggregate offering amount of the shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), issuable under the At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, dated June 7, 2024, by an additional aggregate amount of $705,000. The Company previously sold $3,454…

Other Events. On December 24, 2025, the Company issued a press release announcing the Private Placement. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

Entry Into a Material Definitive Agreement. On December 23, 2025, Dermata Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain institutional and accredited investors for the issuance and sale in a private placement (the “ Private Placement ”) of (i) 1,484,312 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), (ii) pre-funded warrants (“ Pre-Funded Warrants ”) to purch…

Unregistered Sales of Equity Securities. The information contained in

Termination of a Material Definitive Agreement. On November 17, 2025, Dermata Therapeutics, Inc. (the “Company”) sent notice of termination of the License Agreement, dated March 31, 2017, as amended from time to time (the “Agreement”), with Villani, Inc. (“Villani”). The Company elected to terminate the Agreement without cause per the Agreement, and the termination will become effective 90 days after the date of Villani’s receipt of the Company’s notice of termination (the “Termination Date”)…

and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information contained in this

Other Events. On November 7, 2025, Dermata Therapeutics, Inc. (the “Company”) filed a prospectus supplement (the “Current Prospectus Supplement”) to increase the maximum aggregate offering amount of the shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), issuable under the At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, dated June 7, 2024, by an additional aggregate amount of $1,792,315. The Company previously sold $1,6…

Other Events. On September 10, 2025, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing the Company’s strategic pivot to prioritize the development and distribution of over-the-counter (“OTC”) pharmaceutical dermatology focused products that can be sold directly to consumers. The Company plans to initially focus on developing a once weekly acne kit that utilizes an approved OTC monograph active ingredient along with the Company’s Spongilla technology. The Company pla…

and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information contained in this

of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on May 14, 2025, Dermata Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for the prior 30 consecutive business days, the Company was not…

Changes in Registrant’s Certifying Accountant. On June 3, 2025, Dermata Therapeutics, Inc. (the “Company”) was notified that Moss Adams LLP (“Moss Adams”), the Company’s independent registered public accounting firm, merged with Baker Tilly US, LLP, with the merger becoming effective on June 3, 2025. The combined audit practices now operate as Baker Tilly US, LLP (“Baker Tilly”). In connection with the notification of the merger, the audit committee of the Company’s Board of Directors approve…

Forward-Looking Statements This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “aims,” “anticipates,” “believes,” “could,” “expects,” estimates,” “intends,” “may,” “plans,” “potential,” “projects,” “should,” “will,” and “would,” or similar references to future periods. Examples of forward-looking statements in this Current Report on Form 8…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Stockholder’s Equity As previously reported, on March 25, 2025, Dermata Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it was no longer in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market, pursuant to Nasd…

as Exhibit 99.1. The information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information contained in this